Form 4: Avanos Medical SVP Kerr Holbrook Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Kerr Holbrook, SVP and Chief Commercial Officer of Avanos Medical, reports the sale of shares to cover tax obligations upon vesting of restricted stock units.

Summary

  • On March 6, 2025, Kerr Holbrook, SVP and Chief Commercial Officer of Avanos Medical, sold 7,000 shares of common stock at a price of $15.254 per share.
  • Additionally, shares were surrendered to the issuer to satisfy tax withholding obligations upon the vesting of time-based restricted share units (TRSUs).
  • 2,474 shares were surrendered related to TRSUs awarded on March 6, 2023, and 3,590 shares were surrendered related to TRSUs awarded on March 6, 2024.
  • Following these transactions, Holbrook beneficially owns 75,983 shares of Avanos Medical common stock.

Sentiment

Score: 5

Explanation: The document reflects routine transactions related to executive compensation and does not indicate any significant positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives.

Key Dates

DateDescription
03/06/2023Date of TRSU award related to surrendered shares.
03/06/2024Date of TRSU award related to surrendered shares.
03/06/2025Date of stock sale and vesting of TRSUs.
03/10/2025Date of Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.